NCT06819241

Brief Summary

The trial is a 12-month randomized, parallel-group study comparing three arms: (1) HBP self-management with AI chatbot support, (2) HBP self-management without AI chatbot support, and (3) usual care. The primary objective is to evaluate differences in blood pressure changes and medication compliance between groups at 6 and 12 months.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
600

participants targeted

Target at P75+ for not_applicable

Timeline
18mo left

Started Feb 2025

Typical duration for not_applicable

Geographic Reach
1 country

5 active sites

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress45%
Feb 2025Oct 2027

First Submitted

Initial submission to the registry

January 13, 2025

Completed
29 days until next milestone

First Posted

Study publicly available on registry

February 11, 2025

Completed
5 days until next milestone

Study Start

First participant enrolled

February 16, 2025

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 30, 2027

Expected
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 31, 2027

Last Updated

February 11, 2025

Status Verified

February 1, 2025

Enrollment Period

2.2 years

First QC Date

January 13, 2025

Last Update Submit

February 10, 2025

Conditions

Keywords

resistant hypertensionself-management of blood pressure

Outcome Measures

Primary Outcomes (1)

  • Change in HBP (systolic BP and diastolic BP) between baseline and each follow-up visit.

    Primary endpoint

    6 and 12 months

Secondary Outcomes (2)

  • Office blood pressure endpoint

    6 and 12 months

  • Antihypertensive drug compliance endpoint

    6 and 12 months

Study Arms (3)

HBP self-management with AI chatbot support

EXPERIMENTAL

Self-monitoring of HBP combined with AI chatbot responses

Behavioral: AI chatbot support

HBP self-management without AI chatbot support

EXPERIMENTAL

Self-monitoring HBP combined with telemonitoring and case management

Behavioral: telemonitoring and case management

HBP-guided usual care

NO INTERVENTION

Interventions

Integrating the practice of self-monitoring of HBP with the use of AI chatbot responses. This arm includes reminders for patients to monitor their BP and take antihypertensive medications, and involves tracking BP readings over time and offering feedback. Moreover, this arm offers physician-endorsed guidance on modifying the dosage of antihypertensive medication and implementing lifestyle adjustments. It offers education on hypertension and the potential side effects of medication, as well as assistance with medication refills and scheduling appointments.

HBP self-management with AI chatbot support

Combining self-monitoring of HBP with telemonitoring and case management. This arm includes reminders for patients to monitor their BP and take antihypertensive medications, and involves tracking BP readings over time and offering feedback. Moreover, this arm offers physician-endorsed guidance on modifying the dosage of antihypertensive medication and implementing lifestyle adjustments. It offers education on hypertension and the potential side effects of medication, as well as assistance with medication refills and scheduling appointments.

HBP self-management without AI chatbot support

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • ≥18 years of age
  • receiving ≥3 antihypertensive medications of different classes, including a diuretic, and baseline BP \>130/80 mmHg; or receiving ≥ 4 medications regardless of BP

You may not qualify if:

  • unable to conduct self-monitor BP because of cognitive dysfunction
  • poor adherence to medication
  • poor digital capabilities
  • pregnant
  • terminal disease
  • an acute cardiovascular event in the previous 3 months

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (5)

Kaohsiung Medical University Chung-Ho Memorial Hospital

Kaohsiung City, 807, Taiwan

Location

Kaohsiung Veterans General Hospital

Kaohsiung City, 813414, Taiwan

Location

Taichung Veterans General Hospital

Taichung, 407, Taiwan

Location

National Taiwan University Hospital

Taipei, 100, Taiwan

Location

Taipei Veterans General Hospital

Taipei, 112, Taiwan

Location

MeSH Terms

Interventions

Case Management

Intervention Hierarchy (Ancestors)

Patient Care PlanningComprehensive Health CarePatient Care ManagementHealth Services Administration

Central Study Contacts

Wei-Wen Lin, M.D., Ph.D

CONTACT

Hao-Min Cheng, M.D., Ph.D

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 13, 2025

First Posted

February 11, 2025

Study Start

February 16, 2025

Primary Completion (Estimated)

April 30, 2027

Study Completion (Estimated)

October 31, 2027

Last Updated

February 11, 2025

Record last verified: 2025-02

Locations